Revvity Inc

RVTYNYSE
$125.77
1.461.17%
Last update: Sep 14, 1:48 PM
M&A: Human Cell Design (HCD) announced it will be acquired by Revvity (RVTY) on Wednesday, September 9, 2026

Revvity Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revvity (RVTY).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

8Buy
8Hold
Consensus RatingBuy# Analysts16Avg. Consensus PT$117Upside to Avg. PT-6.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026UBSDoug SchenkelAssumesBuyNeutral$120$140
Sep 4, 2026KeybancPaul KnightPT RaiseOverweight$125$165